toxicology of nicotine: chemical mechanism and health effects

Nicotine, a volatile alkaloid produced by plants of the Solanaceae family, sits at the centre of one of the most studied yet still debated toxicological profiles of the twenty-first century. Its molecular formula, C₁₀H₁₄N₂, reveals a pyridine ring linked to a pyrrolidine ring, a configuration that allows it to cross biological membranes with ease and bind selectively to neurotransmitter receptors.

For chemists, toxicologists, and public health professionals alike, understanding the dose-dependent behaviour of nicotine is essential. The compound behaves as a stimulant at low concentrations and as a depressant at higher doses, and its metabolites can persist in biological fluids for days. This dual character shapes both its therapeutic potential in smoking cessation programs and its contribution to disease when consumed regularly through combustible or vaporised products.

Molecular action at cholinergic receptors

The primary mechanism of nicotine toxicity involves its action as an agonist at nicotinic acetylcholine receptors (nAChRs), which are ligand-gated ion channels distributed throughout the central and peripheral nervous systems. When nicotine binds to these receptors, it triggers the influx of sodium and calcium ions, depolarising the cell and releasing a cascade of neurotransmitters, including dopamine, noradrenaline, and serotonin. This surge underlies the reinforcing effects that make nicotine one of the most addictive substances known.

At higher concentrations, sustained receptor activation leads to desensitisation and receptor upregulation, a paradoxical effect that drives tolerance and withdrawal symptoms. Chronic exposure also affects adrenal chromaffin cells, prompting the release of adrenaline and contributing to the cardiovascular strain observed in regular users. Researchers in Sydney and Melbourne have contributed significantly to mapping these receptor subtypes, with several Australian pharmacologists publishing influential work on α4β2 and α7 nAChR isoforms over the past two decades.

Absorption pathways and metabolic fate

Nicotine enters the body rapidly through the alveoli of the lungs when inhaled in cigarette smoke, reaching the brain within ten to twenty seconds. This rapid delivery explains why inhalation produces a more intense pharmacological effect than transdermal patches or oral replacement therapies. The skin, mucous membranes, and gastrointestinal tract also absorb the alkaloid, though at a slower pace.

Hepatic metabolism, primarily mediated by the cytochrome P450 enzyme CYP2A6, converts nicotine into cotinine, a stable metabolite used as a biomarker of exposure in clinical and forensic studies. Genetic polymorphism in CYP2A6 influences smoking behaviour and cessation success, a finding that has informed personalised quit programs run through Australian Quitline services. Renal excretion clears roughly five percent of unchanged nicotine, while the remainder leaves the body as metabolites within sixteen hours of exposure.

Acute toxicity and overdose scenarios

The lethal dose of nicotine in adults is estimated at 40 to 60 milligrams, though survival has been reported after much higher intakes due to vomiting and rapid metabolism. Symptoms of acute poisoning include nausea, salivation, abdominal pain, sweating, and tachycardia, progressing to muscle weakness, seizures, and respiratory failure in severe cases. Children are particularly vulnerable, and accidental ingestion of nicotine e-liquids has prompted tighter packaging rules worldwide.

In Australia, reports of nicotine poisoning rose sharply between 2019 and 2023, largely linked to the surge in vaping among adolescents. The Therapeutic Goods Administration responded by restricting flavours and limiting concentrations, though black-market products remain a concern in cities such as Brisbane and Perth where enforcement is more challenging.

Long-term health consequences

Sustained nicotine use contributes to cardiovascular disease, chronic obstructive pulmonary disorder, and certain forms of cancer, although the alkaloid itself is not classified as a carcinogen. Instead, it promotes tumour growth by activating signalling pathways that increase cell proliferation and inhibit apoptosis. Smokers typically present with depleted plasma levels of antioxidant vitamins, including vitamin C, a deficit commonly measured through ascorbic acid titration in nutritional studies and clinical monitoring.

Pregnancy presents a particularly concerning scenario, as nicotine readily crosses the placental barrier and can impair fetal brain development. Studies conducted through the Royal Women's Hospital in Melbourne have linked prenatal nicotine exposure to attention deficits and respiratory complications in childhood. These findings underscore why Australian clinical guidelines strongly discourage any nicotine product use during gestation.

Regulatory landscape and public health in Australia

Australia has long been a global leader in tobacco control, introducing plain packaging legislation in 2012 and maintaining some of the highest excise taxes on cigarettes in the world. The Therapeutic Goods Administration classifies nicotine for human consumption outside approved therapies as a prescription-only medicine, a framework that places nicotine vaping products under medical supervision rather than general retail.

This regulatory stance, combined with sustained public education campaigns and the services provided by Quitline, has helped reduce adult daily smoking rates to historic lows of around ten percent. Nevertheless, the rapid growth of disposable e-cigarettes among young adults remains a pressing challenge, prompting continued monitoring of usage trends and related toxicological outcomes.

Nicotine occupies a unique space in toxicology, where a single molecule bridges plant defence chemistry, neuropharmacology, addiction medicine, and public policy. Its receptor-level action explains both the difficulty of quitting and the genuine therapeutic role it can play when prescribed responsibly. In Australia, the combination of strict regulation, accessible cessation support, and continuing research ensures that the compound's risks are managed with an evidence-based approach. Understanding the dose-response curve, the metabolic pathway, and the population-level patterns remains the foundation for reducing harm and supporting informed choices.